Cargando…

Evolution of Public Health Human Papillomavirus Immunization Programs in Canada

Background: Since 2007, all Canadian provinces and territories have had a publicly funded program for vaccination against human papillomavirus (HPV) infection. The objective of this study was to describe the evolution of these vaccination programs. Methods: This was a targeted literature review of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Goyette, Alexandra, Yen, Glorian P., Racovitan, Voica, Bhangu, Parambir, Kothari, Smita, Franco, Eduardo L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985769/
https://www.ncbi.nlm.nih.gov/pubmed/33617515
http://dx.doi.org/10.3390/curroncol28010097
_version_ 1783668318380490752
author Goyette, Alexandra
Yen, Glorian P.
Racovitan, Voica
Bhangu, Parambir
Kothari, Smita
Franco, Eduardo L.
author_facet Goyette, Alexandra
Yen, Glorian P.
Racovitan, Voica
Bhangu, Parambir
Kothari, Smita
Franco, Eduardo L.
author_sort Goyette, Alexandra
collection PubMed
description Background: Since 2007, all Canadian provinces and territories have had a publicly funded program for vaccination against human papillomavirus (HPV) infection. The objective of this study was to describe the evolution of these vaccination programs. Methods: This was a targeted literature review of public HPV vaccination programs and vaccination coverage rates, based on information provided by jurisdictional public health authorities. Results: HPV vaccination of schoolgirls began in school years 2007/08 to 2010/11 with three doses of the quadrivalent HPV vaccine in all provinces except Quebec, which started with two doses. By 2018/19, all jurisdictions were vaccinating with two doses of the nonavalent vaccine in both girls and boys, except Quebec, which used a mixed vaccination schedule with one dose of the nonavalent and one dose of the bivalent vaccines. Public HPV vaccination programs in most provinces include after-school catch-up vaccination. Immunocompromised or other high-risk individuals are eligible for the HPV public vaccination program in most provinces, but policies vary by jurisdiction. In 2017/18, vaccination coverage rates in provincial HPV school-based programs varied from 62% in Ontario to 86% in Prince Edward Island in girls and from 58% in Ontario to 86% in Prince Edward Island in boys. Conclusions: Since their introduction, Canadian school-based HPV public vaccination programs have evolved from a three-dose to a two-dose schedule, from a quadrivalent to a nonavalent vaccine, and from a girls-only to a gender-neutral policy. Vaccination coverage rates have varied markedly and only Prince Edward Island and Newfoundland/Labrador have maintained rates exceeding 80%.
format Online
Article
Text
id pubmed-7985769
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79857692021-03-24 Evolution of Public Health Human Papillomavirus Immunization Programs in Canada Goyette, Alexandra Yen, Glorian P. Racovitan, Voica Bhangu, Parambir Kothari, Smita Franco, Eduardo L. Curr Oncol Article Background: Since 2007, all Canadian provinces and territories have had a publicly funded program for vaccination against human papillomavirus (HPV) infection. The objective of this study was to describe the evolution of these vaccination programs. Methods: This was a targeted literature review of public HPV vaccination programs and vaccination coverage rates, based on information provided by jurisdictional public health authorities. Results: HPV vaccination of schoolgirls began in school years 2007/08 to 2010/11 with three doses of the quadrivalent HPV vaccine in all provinces except Quebec, which started with two doses. By 2018/19, all jurisdictions were vaccinating with two doses of the nonavalent vaccine in both girls and boys, except Quebec, which used a mixed vaccination schedule with one dose of the nonavalent and one dose of the bivalent vaccines. Public HPV vaccination programs in most provinces include after-school catch-up vaccination. Immunocompromised or other high-risk individuals are eligible for the HPV public vaccination program in most provinces, but policies vary by jurisdiction. In 2017/18, vaccination coverage rates in provincial HPV school-based programs varied from 62% in Ontario to 86% in Prince Edward Island in girls and from 58% in Ontario to 86% in Prince Edward Island in boys. Conclusions: Since their introduction, Canadian school-based HPV public vaccination programs have evolved from a three-dose to a two-dose schedule, from a quadrivalent to a nonavalent vaccine, and from a girls-only to a gender-neutral policy. Vaccination coverage rates have varied markedly and only Prince Edward Island and Newfoundland/Labrador have maintained rates exceeding 80%. MDPI 2021-02-22 /pmc/articles/PMC7985769/ /pubmed/33617515 http://dx.doi.org/10.3390/curroncol28010097 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Goyette, Alexandra
Yen, Glorian P.
Racovitan, Voica
Bhangu, Parambir
Kothari, Smita
Franco, Eduardo L.
Evolution of Public Health Human Papillomavirus Immunization Programs in Canada
title Evolution of Public Health Human Papillomavirus Immunization Programs in Canada
title_full Evolution of Public Health Human Papillomavirus Immunization Programs in Canada
title_fullStr Evolution of Public Health Human Papillomavirus Immunization Programs in Canada
title_full_unstemmed Evolution of Public Health Human Papillomavirus Immunization Programs in Canada
title_short Evolution of Public Health Human Papillomavirus Immunization Programs in Canada
title_sort evolution of public health human papillomavirus immunization programs in canada
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985769/
https://www.ncbi.nlm.nih.gov/pubmed/33617515
http://dx.doi.org/10.3390/curroncol28010097
work_keys_str_mv AT goyettealexandra evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada
AT yenglorianp evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada
AT racovitanvoica evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada
AT bhanguparambir evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada
AT kotharismita evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada
AT francoeduardol evolutionofpublichealthhumanpapillomavirusimmunizationprogramsincanada